Drugs / scAAV9.U7.ACCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04240314 | Jan 2020 → Nov 2023 | Duchenne muscular dystrophy | Megan Waldrop | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | scAAV9.U7.ACCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04240314 ↗ |
| Route | Intravenous | “systemically delivered via a peripheral vein injection.” NCT04240314 ↗ |
| Target | DMD | “The proposed clinical trial is a systemic (intravenous) delivery of scAAV9.U7.ACCA for DMD patients with a duplication of exon 2 in the DMD gene. Preclinical data shows that...” NCT04240314 ↗ |